Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells

Autor: Maria Molina-Molina, Roger Llatjós, Ignacio Escobar, P. Luburich-Hernaiz, Vanesa Vicens-Zygmunt, E. Sala-Llinas, Jordi Dorca, Ana Montes-Worboys, C. Machahua-Huamani

Publikováno v: Recercat. Dipósit de la Recerca de Catalunya
instname
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-13 (2018)
BMC Pulmonary Medicine
Dipòsit Digital de la UB
Universidad de Barcelona

Background: Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibroblast proliferation could be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::899bd058433e8630ceaa203696005937
https://doi.org/10.1186/s12890-018-0626-4